The scientists attached with Council of Scientific and Industrial Research (CSIR) has bagged two US patents in the area of drug development. While the first patent relates to an inclusion complex of Rifampicin with cyclodextrin (CD) that can be used as an anti-tubercular drug, the other comes for developing a method for treating drug induced hepatotoxicity.

The first invention relates to an inclusion complex of Rifampicin with cyclodextrin (CD) that can be used as an anti-tubercular drug. It also relates to a process for synthesizing inclusion complexes of the anti-tubercular drug, Rifampicin, with â-CD (â-cyclodextrin) and HP-â-CD (2-hydroxy propyl cyclodextrin) and characterization of these inclusion complexes. In addition, a further aspect of the invention is to provide a general process for preparing inclusion complexes of cyclodextrin with large size molecules.

The second patent was for the development of a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and method of treating drug induced hepatotoxicity.

The scientists who have been given credit for the inventions include Kakulapati Rama Rao, Nanduri Bhanumathi, Jhillu Singh Yadav, Neelam Srilakshmi Krishnaveni (all for Patent No: 7,001,893), Rakseh Kamal Johri, Sheikh Tasaduq Abdullah, Kuldeep Singh, Devinder Kumar Gupta, Bal Krishan Kapahi, Dilip Manikrao Mondhe, Satinder Mohan Jain, Om Prakash Suri, Kasturi Lal Bedi and Ghulam Nabi Qazi (Patent No:7,001,619)